Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Core Viewpoint - Tiziana Life Sciences is actively participating in the 37th Annual ROTH Conference, showcasing its lead candidate, intranasal foralumab, which is a fully human anti-CD3 monoclonal antibody aimed at treating neuroinflammatory diseases [1][2]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies through alternative drug delivery technologies, particularly in immunotherapy [4]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in prior studies [4]. Product Development - Foralumab has shown the ability to stimulate T regulatory cells when administered intranasally, with 10 patients suffering from Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) already dosed in an open-label Expanded Access Program, showing either improvement or stability of disease within 6 months [2]. - The FDA has approved the enrollment of an additional 20 patients in the Expanded Access Program for foralumab [2]. - A Phase 2a randomized, double-blind, placebo-controlled trial for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis is currently underway [2][3]. Mechanism of Action - Foralumab binds to the T cell receptor, modulating T cell function and dampening inflammation, which is beneficial in treating conditions like COVID-19 and multiple sclerosis [3]. - The immunomodulation approach using nasal anti-CD3 monoclonal antibodies represents a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [3]. Conference Participation - The CEO of Tiziana Life Sciences, Ivor Elrifi, will present during a fireside chat at the ROTH Conference and will host 1x1 investor meetings, indicating the company's commitment to engaging with investors and stakeholders [1].